Seeking to unite FDA efforts to combat antimicrobial resistance (AMR), Commissioner Scott Gottlieb outlined a new strategy to use stewardship and science to slow the threat's pace and reduce its impact. The plan seeks to better facilitate and pep up new antimicrobial product development as the field wrestles with new ideas about how to overcome the market's discouraging economics.